Reata Appoints Charles A. Sanders, M.D. to its Board of Directors
DALLAS, TX -- June 1, 2005 -- Reata Pharmaceuticals, Inc. today announced that Charles A. Sanders, M.D. has been named to the Company's Board of Directors. Dr. Sanders is the former chairman and CEO of Glaxo Inc., as well as a former member of the board of Glaxo plc.
"Dr. Sanders has been involved in building two major pharmaceutical companies and managing one of the largest medical centers in the world. His experience should be of enormous help to us," said Warren Huff, President and Chief Executive Officer of Reata. "We are delighted that he has joined our board."
Before joining Glaxo Inc., Dr. Sanders spent eight years with Squibb Corp. where he held a number of posts including the position of vice chairman. He also served as chief executive officer of the science and technology group and chairman of the science and technology committee of Squibb's Board. Prior to this, Dr. Sanders was general director of Massachusetts General Hospital and professor of medicine at Harvard Medical School. A native of Dallas, he is a graduate of Southwestern Medical College of the University of Texas. Dr. Sanders is past chairman of the New York Academy of Sciences, past chairman of The Commonwealth Fund, and past chairman of the Overseers Committee to Visit the Harvard Medical School. He is currently a member of the Institute of Medicine of the National Academy of Sciences, a member of the CSIS Board of Trustees, chairman of Project HOPE, and chairman of the Foundation for the National Institutes of Health. In addition, he serves on the boards of Genentech, Vertex Pharmaceuticals, BioPure, Trimeris, Cephalon, and Fisher Scientific International. In the past Dr. Sanders has served on the boards of several multi-national corporations, including Merrill Lynch and Company, Morton International Inc, and Reynolds Metals Company.
About Reata
Reata Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development of novel treatments for cancer, inflammation, and neurodegenerative diseases. Founded in 2002, Reata is developing five classes of cancer drugs licensed from leading academic institutions. The company's most advanced products, RTA 744 for primary brain cancer and RTA 401 for hematological cancers and solid tumors, are entering clinical trials in mid-2005. Clinical testing of additional products, including RTA 402 for inflammation, is expected to begin in late 2005 or early 2006. Reata is also using a proprietary drug screening platform to identify novel molecules that reactivate misfolded proteins involved in cancer and neurodegenerative disease.
For more information, press only:
Warren Huff
(972) 865-2200
#########
